Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500, Nasdaq advance as soft inflation tempers Fed rate-hike bets
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- HPE raises networking revenue outlook, secures $1.2B Vultr order
Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 2c, Revenues Miss; Offers FY20 Revenue Outlook
October 28, 2020 4:04 PM EDTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of $0.11, $0.02 better than the analyst estimate of $0.09. Revenue for the quarter came in at $60.31 million versus the consensus estimate of $63.95 million.
Key Financial and Corporate Highlights
Third Quarter of 2020
Total net product sales from HETLIOZ® and... More